(CL) Colgate-Palmolive - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1941621039
Stock: Oral Care, Personal Care, Home Care, Pet Food
Total Rating 63
Risk 87
Buy Signal -0.38
| Risk 5d forecast | |
|---|---|
| Volatility | 24.0% |
| Relative Tail Risk | -2.30% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.01 |
| Alpha | 1.08 |
| Character TTM | |
|---|---|
| Beta | -0.157 |
| Beta Downside | -0.321 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.05% |
| CAGR/Max DD | 0.35 |
EPS (Earnings per Share)
Revenue
Description: CL Colgate-Palmolive March 05, 2026
Colgate-Palmolive Company (CL) manufactures and sells consumer products globally, operating in two segments: Oral, Personal and Home Care, and Pet Nutrition.
The Oral, Personal and Home Care segment includes toothpaste, soaps, shampoos, and household cleaners. Products are sold under various brands, such as Colgate and Palmolive, through retail, wholesale, and e-commerce channels. This segment operates in the consumer staples sector, characterized by consistent demand for essential goods.
The Pet Nutrition segment offers pet food under the Hills Science Diet and Hills Prescription Diet brands. Distribution occurs via pet supply retailers, veterinarians, and e-commerce. The pet care market demonstrates resilience, with pet ownership and spending on pet health remaining strong.
For more detailed financial analysis, consider exploring ValueRay.
Headlines to watch out for
- Global oral care market share dictates revenue growth
- Raw material cost fluctuations impact profit margins
- Pet nutrition segment expansion drives premium sales
- Foreign exchange rates influence international earnings
- Regulatory changes in product safety affect manufacturing costs
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 2.13b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA 0.15 > 1.0 |
| NWC/Revenue: -0.13% < 20% (prev -2.20%; Δ 2.07% < -1%) |
| CFO/TA 0.26 > 3% & CFO 4.20b > Net Income 2.13b |
| Net Debt (6.70b) to EBITDA (3.77b): 1.78 < 3 |
| Current Ratio: 1.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (804.7m) vs 12m ago -2.16% < -2% |
| Gross Margin: 60.11% > 18% (prev 0.61%; Δ 5.95k% > 0.5%) |
| Asset Turnover: 125.9% > 50% (prev 125.3%; Δ 0.64% > 0%) |
| Interest Coverage Ratio: 11.73 > 6 (EBITDA TTM 3.77b / Interest Expense TTM 268.0m) |
Altman Z'' 8.35
| A: -0.00 (Total Current Assets 5.71b - Total Current Liabilities 5.74b) / Total Assets 16.33b |
| B: 1.63 (Retained Earnings 26.59b / Total Assets 16.33b) |
| C: 0.19 (EBIT TTM 3.14b / Avg Total Assets 16.19b) |
| D: 1.67 (Book Value of Equity 26.59b / Total Liabilities 15.96b) |
| Altman-Z'' Score: 8.35 = AAA |
Beneish M -3.11
| DSRI: 1.09 (Receivables 1.68b/1.52b, Revenue 20.38b/20.10b) |
| GMI: 1.01 (GM 60.11% / 60.51%) |
| AQI: 0.93 (AQ_t 0.37 / AQ_t-1 0.39) |
| SGI: 1.01 (Revenue 20.38b / 20.10b) |
| TATA: -0.13 (NI 2.13b - CFO 4.20b) / TA 16.33b) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of CL shares?
As of March 18, 2026, the stock is trading at USD 89.94 with a total of 5,236,541 shares traded.
Over the past week, the price has changed by -2.76%, over one month by -5.97%, over three months by +13.50% and over the past year by +1.59%.
Over the past week, the price has changed by -2.76%, over one month by -5.97%, over three months by +13.50% and over the past year by +1.59%.
Is CL a buy, sell or hold?
Colgate-Palmolive has received a consensus analysts rating of 3.77.
Therefor, it is recommend to hold CL.
- StrongBuy: 7
- Buy: 6
- Hold: 7
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the CL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 97.2 | 8.1% |
| Analysts Target Price | 97.2 | 8.1% |
CL Fundamental Data Overview March 17, 2026
P/E Trailing = 33.7795
P/E Forward = 22.9358
P/S = 3.4937
P/B = 1318.6949
P/EG = 3.4219
Revenue TTM = 20.38b USD
EBIT TTM = 3.14b USD
EBITDA TTM = 3.77b USD
Long Term Debt = 7.99b USD (from longTermDebt, last quarter)
Short Term Debt = 1.12b USD (from shortLongTermDebt, last quarter)
Debt = 7.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.70b USD (from netDebt column, last quarter)
Enterprise Value = 77.91b USD (71.21b + Debt 7.99b - CCE 1.29b)
Interest Coverage Ratio = 11.73 (Ebit TTM 3.14b / Interest Expense TTM 268.0m)
EV/FCF = 21.44x (Enterprise Value 77.91b / FCF TTM 3.63b)
FCF Yield = 4.66% (FCF TTM 3.63b / Enterprise Value 77.91b)
FCF Margin = 17.83% (FCF TTM 3.63b / Revenue TTM 20.38b)
Net Margin = 10.46% (Net Income TTM 2.13b / Revenue TTM 20.38b)
Gross Margin = 60.11% ((Revenue TTM 20.38b - Cost of Revenue TTM 8.13b) / Revenue TTM)
Gross Margin QoQ = 60.15% (prev 59.42%)
Tobins Q-Ratio = 4.77 (Enterprise Value 77.91b / Total Assets 16.33b)
Interest Expense / Debt = 0.80% (Interest Expense 64.0m / Debt 7.99b)
Taxrate = 26.09% (798.0m / 3.06b)
NOPAT = 2.32b (EBIT 3.14b * (1 - 26.09%))
Current Ratio = 1.00 (Total Current Assets 5.71b / Total Current Liabilities 5.74b)
Debt / Equity = 147.9 (Debt 7.99b / totalStockholderEquity, last quarter 54.0m)
Debt / EBITDA = 1.78 (Net Debt 6.70b / EBITDA 3.77b)
Debt / FCF = 1.84 (Net Debt 6.70b / FCF TTM 3.63b)
Total Stockholder Equity = 493.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.16% (Net Income 2.13b / Total Assets 16.33b)
RoE = 431.6% (Net Income TTM 2.13b / Total Stockholder Equity 493.8m)
RoCE = 37.07% (EBIT 3.14b / Capital Employed (Equity 493.8m + L.T.Debt 7.99b))
RoIC = 26.25% (NOPAT 2.32b / Invested Capital 8.85b)
WACC = 4.86% (E(71.21b)/V(79.20b) * Re(5.34%) + D(7.99b)/V(79.20b) * Rd(0.80%) * (1-Tc(0.26)))
Discount Rate = 5.34% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.24%
[DCF] Terminal Value 87.29% ; FCFF base≈3.60b ; Y1≈3.98b ; Y5≈5.17b
[DCF] Fair Price = 182.0 (EV 152.55b - Net Debt 6.70b = Equity 145.85b / Shares 801.5m; r=5.90% [WACC]; 5y FCF grow 12.34% → 2.90% )
EPS Correlation: 93.07 | EPS CAGR: 6.89% | SUE: 2.37 | # QB: 1
Revenue Correlation: 91.01 | Revenue CAGR: 4.72% | SUE: 2.24 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.97 | Chg7d=-0.001 | Chg30d=-0.001 | Revisions Net=+2 | Analysts=15
EPS current Year (2026-12-31): EPS=3.88 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=+2 | Growth EPS=+5.2% | Growth Revenue=+4.3%
EPS next Year (2027-12-31): EPS=4.15 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+3 | Growth EPS=+6.9% | Growth Revenue=+3.4%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.0% (Discount Rate 7.9% - Earnings Yield 3.0%)
[Growth] Growth Spread = -0.6% (Analyst 4.3% - Implied 5.0%)
P/E Forward = 22.9358
P/S = 3.4937
P/B = 1318.6949
P/EG = 3.4219
Revenue TTM = 20.38b USD
EBIT TTM = 3.14b USD
EBITDA TTM = 3.77b USD
Long Term Debt = 7.99b USD (from longTermDebt, last quarter)
Short Term Debt = 1.12b USD (from shortLongTermDebt, last quarter)
Debt = 7.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.70b USD (from netDebt column, last quarter)
Enterprise Value = 77.91b USD (71.21b + Debt 7.99b - CCE 1.29b)
Interest Coverage Ratio = 11.73 (Ebit TTM 3.14b / Interest Expense TTM 268.0m)
EV/FCF = 21.44x (Enterprise Value 77.91b / FCF TTM 3.63b)
FCF Yield = 4.66% (FCF TTM 3.63b / Enterprise Value 77.91b)
FCF Margin = 17.83% (FCF TTM 3.63b / Revenue TTM 20.38b)
Net Margin = 10.46% (Net Income TTM 2.13b / Revenue TTM 20.38b)
Gross Margin = 60.11% ((Revenue TTM 20.38b - Cost of Revenue TTM 8.13b) / Revenue TTM)
Gross Margin QoQ = 60.15% (prev 59.42%)
Tobins Q-Ratio = 4.77 (Enterprise Value 77.91b / Total Assets 16.33b)
Interest Expense / Debt = 0.80% (Interest Expense 64.0m / Debt 7.99b)
Taxrate = 26.09% (798.0m / 3.06b)
NOPAT = 2.32b (EBIT 3.14b * (1 - 26.09%))
Current Ratio = 1.00 (Total Current Assets 5.71b / Total Current Liabilities 5.74b)
Debt / Equity = 147.9 (Debt 7.99b / totalStockholderEquity, last quarter 54.0m)
Debt / EBITDA = 1.78 (Net Debt 6.70b / EBITDA 3.77b)
Debt / FCF = 1.84 (Net Debt 6.70b / FCF TTM 3.63b)
Total Stockholder Equity = 493.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.16% (Net Income 2.13b / Total Assets 16.33b)
RoE = 431.6% (Net Income TTM 2.13b / Total Stockholder Equity 493.8m)
RoCE = 37.07% (EBIT 3.14b / Capital Employed (Equity 493.8m + L.T.Debt 7.99b))
RoIC = 26.25% (NOPAT 2.32b / Invested Capital 8.85b)
WACC = 4.86% (E(71.21b)/V(79.20b) * Re(5.34%) + D(7.99b)/V(79.20b) * Rd(0.80%) * (1-Tc(0.26)))
Discount Rate = 5.34% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.24%
[DCF] Terminal Value 87.29% ; FCFF base≈3.60b ; Y1≈3.98b ; Y5≈5.17b
[DCF] Fair Price = 182.0 (EV 152.55b - Net Debt 6.70b = Equity 145.85b / Shares 801.5m; r=5.90% [WACC]; 5y FCF grow 12.34% → 2.90% )
EPS Correlation: 93.07 | EPS CAGR: 6.89% | SUE: 2.37 | # QB: 1
Revenue Correlation: 91.01 | Revenue CAGR: 4.72% | SUE: 2.24 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.97 | Chg7d=-0.001 | Chg30d=-0.001 | Revisions Net=+2 | Analysts=15
EPS current Year (2026-12-31): EPS=3.88 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=+2 | Growth EPS=+5.2% | Growth Revenue=+4.3%
EPS next Year (2027-12-31): EPS=4.15 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+3 | Growth EPS=+6.9% | Growth Revenue=+3.4%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.0% (Discount Rate 7.9% - Earnings Yield 3.0%)
[Growth] Growth Spread = -0.6% (Analyst 4.3% - Implied 5.0%)